Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lixivaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 known ✓ | P30518 | 19/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 16/20 | 1.00 |
| ▸ | OXTR | P30559 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lixivaptan SCHEMBL29377065 | 1.00 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29373157 | 1.00 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29387791 | 1.00 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL7335432 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL7341103 | 0.92 | AVPR2 (0.90) | AVPR2AVPR1AOXTR | |
| SCHEMBL8313381 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL8316894 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL7339573 | 0.91 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL13590881 | 0.90 | AVPR2 (0.86) | AVPR2AVPR1AOXTR | |
| SCHEMBL7339348 | 0.90 | AVPR2 (0.86) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656931-B2 | N-(4-(5H-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11H) ylcarbonyl)-3-chlorophenyl)-5-fluoro-2-methylbenzamide | WYETH HOLDINGS CORPORATION | 2003-12-02 | — | — | US | claimed |
| US-20030069227-A1 | Vasopressin antagonist and diuretic combination | AMERICAN CYANAMID COMPANY | 2003-04-10 | — | — | US | claimed |
| US-6420358-B1 | INCREASING URINE FLOW IN A HUMAN WHILE INHIBITING LOSS OF ELECTROLYTES OR IONS, EDEMA, HYPERTENSION | AMERICAN CYANAMID COMPANY | 2002-07-16 | — | — | US | claimed |
| EP-1216033-A1 | VASOPRESSIN ANTAGONIST FORMULATION AND PROCESS | American Cyanamid Company (US) | 2002-06-26 | — | — | EP | claimed |
| US-6352718-B1 | VPA-985, SURFACTANT, POLYOXYETHYLENE GLYCOL, SUCROSE FATTY ACID ESTER AND/OR POLYVINYLPYRROLIDONE | AMERICAN CYANAMID COMPANY | 2002-03-05 | — | — | US | claimed |
| WO-2001022945-A1 | VASOPRESSIN ANTAGONIST FORMULATION AND PROCESS | AMERICAN CYANAMID COMPANY (US) | 2001-04-05 | — | — | WO | claimed |
| EP-0636625-B1 | Tricyclic diazepines vasopressin and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1999-01-27 | — | — | EP | claimed |
| US-5624923-A | UROGENITAL AND CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-04-29 | — | — | US | claimed |
| US-5516774-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-05-14 | — | — | US | claimed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | claimed |
| US-20250114470-A1 | THERAPY FOR POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF MASSACHUSETTS | 2025-04-10 | — | — | US | disclosed |
| US-20220110944-A1 | FORMULATIONS OF LIXIVAPTAN FOR THE TREATMENT OF POLYCYSTIC DISEASE | PALLADIO BIOSCIENCES, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11241441-B2 | Formulations of lixivaptan for the treatment of polycystic disease | PALLADIO BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241441-B2 | Formulations of lixivaptan for the treatment of polycystic disease | PALLADIO BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-5968930-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5968937-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1998020011-A1 | 3-CARBOXAMIDE DERIVATIVES OF 5H-PYRROLO[2,1-c][1,4]-BENZODIAZEPINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5516774-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241441-B2 | Formulations of lixivaptan for the treatment of polycystic disease | LPXN, PKD1, PKD2 | AVPR2 12/4885AVPR1A 11/4885OXTR 631/4885 |
| US-20030069227-A1 | Vasopressin antagonist and diuretic combination | AVPR2, AVPR1B, AVPR1A | AVPR2 1/4885AVPR1A 3/4885OXTR 90/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885OXTR 663/4885 |
| US-20220110944-A1 | FORMULATIONS OF LIXIVAPTAN FOR THE TREATMENT OF POLYCYSTIC DISEASE | LPXN, PKD1, PKD2 | AVPR2 12/4885AVPR1A 11/4885OXTR 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.